Blog

Nativo Resources (LSE:NTVO) has announced new assay results from underground sampling at its Bonanza Gold Mine, part of the Tesoro concession in southern Peru. Certified laboratory testing returned standout grades of up to 73.4 g/t gold, alongside notable silver values, confirming the presence of bonanza-grade mineralisation within structurally controlled zones of the Bonanza vein system.

These findings strengthen the company’s geological interpretation, demonstrating continuity of high-grade mineralisation from surface exposures into underground workings and pointing to potential extensions at depth. Together with earlier sampling results and existing stockpiled material, the data support a selective narrow-vein mining strategy. This approach is aimed at reducing dilution, focusing on high-margin zones, and enabling early-stage cash flow as the company moves toward initial production and sales targeted for the second quarter of 2026.

Despite encouraging operational progress, the company’s financial profile remains a key constraint, with ongoing losses, negative equity, relatively high leverage compared to asset levels, and continued cash burn. Market indicators offer limited support, reflecting a short-term recovery in the share price, though momentum appears stretched and the stock remains below its 200-day average. Valuation also remains challenging due to negative earnings and the absence of dividend support.

More about Nativo Resources plc

Nativo Resources plc is a London-listed gold mining company focused on projects in Peru. The company is engaged in primary gold extraction, ore processing, and the recovery of gold from tailings. Its near-term strategy centres on scaling production at the Tesoro Gold Concession, including the Bonanza and Morrocota mines, as it works toward establishing sustainable operations and revenue generation.

CAB Payments (LSE:CABP) has received a revised non-binding and final indicative cash offer from StoneX Group at 110 pence per share, valuing the business at around £287 million. The proposal implies a premium of 52% to the undisturbed share price prior to an earlier approach, 43% above the 52-week high, and 29% higher than the existing firm offer from the Helios Consortium.

Following discussions with its advisers, the company’s independent board stated it would be inclined to recommend a formal offer from StoneX at this level, subject to satisfactory due diligence and agreement on final terms. The board has also encouraged the Helios Consortium to engage with StoneX, noting the enhanced value for shareholders. However, it emphasised that there is no guarantee a binding offer will materialise and advised investors not to take any action at this stage.

From a financial perspective, the company presents a mixed outlook. While it maintains a solid balance sheet with relatively low leverage, performance has been impacted by volatile cash flows and inconsistent revenue and margin trends. Market indicators offer some support, with the share price trading above key moving averages, while valuation appears reasonable on a price-to-earnings basis, though the absence of dividend yield data limits further assessment.

More about CAB Payments Holdings Limited

CAB Payments Holdings PLC operates within the financial services sector, specialising in cross-border payments and foreign exchange solutions. The company focuses on enabling transactions in emerging and less accessible markets, providing infrastructure and services to financial institutions and corporate clients with complex international payment requirements.

Mila Resources (LSE:MILA) has announced early results from its Q1 2026 reverse circulation drilling programme at the Yarrol Gold Project in Queensland, confirming gold mineralisation at the southernmost drill locations at Yarrol North. These results extend the known strike length of the system to more than than 500 metres, with mineralisation remaining open in all directions. Broad zones of gold, including higher-grade intercepts at the southern edge, are being incorporated—alongside pending assay data from additional infill and step-out drilling—into the dataset required for a maiden JORC-compliant mineral resource estimate.

At the Monal West licence, initial rock chip sampling at the Jazza target has identified anomalous gold, copper, and silver values, accompanied by elevated levels of molybdenum, zinc, and tungsten. This geochemical profile is consistent with the presence of a deeper porphyry system and related epithermal mineralisation. Backed by a significant inherited induced polarisation (IP) geophysical anomaly, the findings point to the possibility of a larger mineralised system. Mila plans to carry out targeted ground-based geophysical surveys to refine drill targets and advance both Yarrol and Monal West toward resource definition, supporting the broader growth potential of its Queensland assets.

The company’s outlook remains constrained by its financial position, characterised by a lack of revenue, ongoing losses, and continued negative free cash flow, alongside weak technical indicators such as a share price below key moving averages and a negative MACD. However, a relatively low level of debt and a stable equity base provide some underlying support, even as valuation remains difficult to justify given negative earnings and the absence of dividend yield.

More about Mila Resources

Mila Resources Plc is a London-listed gold exploration company focused on developing gold and copper projects in Queensland, Australia. Its primary asset, the Yarrol Gold Project, is advancing toward an initial JORC-compliant resource estimate, supported by additional exploration across its wider licence portfolio, including the prospective Monal West porphyry corridor.

Hays plc (LSE:HAS) has published its trading update for the quarter ended 31 March 2026, offering insight into recent business performance. The statement is available via the London Stock Exchange and the company’s investor relations platform, and has also been filed with the UK regulator’s National Storage Mechanism.

The group will host a conference call for analysts and investors on 16 April 2026 to discuss the latest developments in more detail. A recorded replay will be made accessible through its investor results centre, reflecting Hays’s ongoing commitment to maintaining open communication with the market.

From an outlook perspective, the company faces pressure from weak technical indicators, with the share price trading below key moving averages and a negative MACD signal. Valuation also appears stretched, with a notably high price-to-earnings ratio of 748.65. Financial performance presents a mixed picture, with declining revenue and continued losses offset to some extent by improvements in free cash flow.

More about Hays plc

Hays plc is a global recruitment and workforce solutions provider, specialising in placing skilled professionals across a wide range of industries. The company operates across both permanent and temporary hiring markets, serving private and public sector clients in multiple regions worldwide.

Oriole Resources (LSE:ORR) has released new exploration findings from its 90%-owned Eastern Central Licence Package in Cameroon, located close to its 1.23-million-ounce Mbe gold resource. Ongoing work across the Ndom, Pokor, and Niambaram licences is reinforcing the potential for a large-scale gold system that could meaningfully increase the company’s overall resource base if current targets are validated.

At the Ndom licence, selective rock-chip sampling has delivered grades of up to 17 grams per tonne gold from quartz veins that display structural characteristics similar to those seen at Mbe. These results have led to the planning of additional follow-up exploration. Meanwhile, at Pokor and Niambaram, soil and rock-chip programmes have identified lower-grade anomalies, with further mapping and assay work scheduled through 2026 to refine drill targets and guide future exploration priorities.

From a financial standpoint, the company remains constrained by its lack of revenue generation and continued cash outflows, although it benefits from a relatively low level of debt. Technical signals provide some support, indicating moderate momentum, but valuation remains limited by negative earnings and the absence of dividend indicators.

More about Oriole Resources PLC

Oriole Resources PLC is an AIM-listed gold exploration and development company with a focus on Central and West Africa. Its flagship asset is the Mbe orogenic gold project in Cameroon, which hosts an inferred mineral resource of 1.23 million ounces. The company also holds a broader portfolio of early-stage exploration licences within the Eastern Central Licence Package, targeting further discoveries to build scale in the region.

Creo Medical (LSE:CREO) has agreed to sell its UK-based manufacturing division to a newly established company led by its current manufacturing management team, as part of a management buyout. Around 25 employees will transfer to the new entity, with production of Creo’s devices continuing under an outsourced model. The transaction reflects the company’s transition toward a leaner structure focused on product development and commercialisation, while maintaining operational continuity and technical expertise.

The outsourcing arrangement is expected to deliver annual cost savings exceeding £1 million, representing an additional 15% reduction based on the FY25 closing run-rate on a pro forma basis. This builds on an estimated 40% cost reduction already achieved since FY24. By maintaining a close relationship with the new manufacturing business—where CEO Craig Gulliford will take on a non-executive role—Creo aims to scale production efficiently while concentrating resources on innovation and sales growth, reinforcing its position in the advanced medical device sector.

Despite these operational efficiencies, the company’s financial outlook remains under pressure, with declining revenues, significant losses, and continued cash outflows. Market indicators offer some support, with a strong upward trend and positive MACD, although a high RSI suggests the stock may be overbought in the near term. The overall valuation impact is unclear, as key metrics such as price-to-earnings ratio and dividend yield are not currently available.

More about Creo Medical

Creo Medical Group is a UK-based medical technology company specialising in minimally invasive electrosurgical devices used in endoscopic procedures for pre-cancerous and cancerous conditions. Its CROMA platform, built on Kamaptive technology, combines multiple energy sources—including radiofrequency and microwave—into a single system to enable precise cutting, coagulation, dissection, and ablation. The company is focused on advancing a portfolio of patented solutions aimed at improving clinical outcomes while reducing the invasiveness and cost of surgical and endoscopic treatments.

Genedrive plc (LSE:GDR) has confirmed that its CYP2C19 ID Kit will be introduced at North Bristol NHS Trust’s Southmead Hospital, specifically within its Hyperacute and Acute Stroke Units. The rollout is supported by £80,000 in funding from the Medlock Charitable Trust, chaired by major shareholder David Medlock. The initiative is expected to benefit around 1,500 stroke patients treated at the hospital each year by helping clinicians quickly determine which individuals may not respond effectively to clopidogrel, a commonly prescribed antiplatelet drug.

The funding will be administered through Southmead Hospital Charity, which enables enhancements to patient care beyond standard NHS resources. Meanwhile, the hospital’s stroke team is preparing a proposal to secure longer-term funding through the local Integrated Care Board once the initial programme concludes. Leaders from Genedrive, the Medlock Charitable Trust, and Bristol’s NHS services подчеркнули that the collaboration brings advanced point-of-care genetic testing into stroke aftercare, with the goal of tailoring treatment decisions, improving patient outcomes, and potentially lowering overall healthcare costs. The move also reinforces Genedrive’s role in advancing precision medicine within NHS pathways.

From a financial standpoint, the company continues to face challenges, including persistent losses, ongoing cash outflows, and a declining equity base, albeit with limited debt exposure. Market indicators suggest some near-term strength, with the share price trading above key averages and a positive MACD reading, though a high RSI points to possible short-term overextension. Valuation remains difficult to justify given negative earnings and the absence of a meaningful price-to-earnings ratio.

More about Genedrive

Genedrive plc is a UK-based diagnostics company focused on pharmacogenetic testing solutions designed for rapid use at the point of care. Its products aim to support safer and more effective prescribing in acute and emergency settings. Key offerings include the CYP2C19 ID Kit, used to guide antiplatelet therapy in stroke patients, and the MT-RNR1 ID Kit, which helps prevent antibiotic-related hearing loss in newborns. The company is working to integrate precision diagnostics into routine NHS practice while also pursuing opportunities for international expansion.

Mindflair plc (LSE:MFAI) has revealed that Sure Valley Ventures Fund III, in which it is an investor, has led a $1.8 million pre-seed funding round for Audrey AI, a Dublin-based startup focused on building an AI-driven platform for financial auditors. The capital injection will support the scaling of Audrey AI’s technology and the expansion of its engineering and audit-focused teams as it grows its presence across Ireland, the UK, and other international markets.

Audrey AI is targeting the global financial audit sector, valued at over $100 billion, where many workflows remain heavily manual. Its agentic AI platform is designed to automate key audit functions such as evidence collection and testing. Early pilot programmes with Top 10 and Top 20 audit firms have reportedly reduced time spent on data gathering, validation, and detailed testing by more than 85%, suggesting strong potential for the platform to become a critical tool for firms facing staffing constraints and margin pressures.

For Mindflair, the investment aligns with its strategy of backing AI solutions that address complex challenges within regulated industries. The move highlights increasing investor focus on specialised AI applications capable of handling nuanced, domain-specific tasks that go beyond general-purpose systems, potentially improving both efficiency and audit quality across the accounting landscape.

However, the company’s outlook remains tempered by limited visibility on revenue and weak cash-flow conversion, despite a notable rebound in reported profitability and a relatively low level of leverage. Market indicators point to a bearish technical setup, with the share price trading below key averages and a negative MACD reading. While valuation may appear low on a price-to-earnings basis, concerns around earnings quality reduce confidence in that metric.

More about Mindflair plc

Mindflair plc is an AIM-listed investment firm offering exposure to a portfolio of emerging technology businesses centred on artificial intelligence. Its investment approach focuses on high-growth areas such as the Internet of Things, cybersecurity, machine learning, immersive technologies, and big data, targeting companies with strong commercial traction and the potential to scale rapidly.